Daniele Anderson, MD
Neurology · Lake Barrington, ILNPI 1588689285
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,138 of the $191,463 with a category attached, or 87.3%. AbbVie accounts for 75.8% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2021 at $57,774 and has fallen 76.9% since, to $13,364 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 990 payments — averaging $193.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$145K
- Biohaven Pharmaceuticals, Inc.$23K
- Biohaven Pharmaceutical Holding Company Ltd.$14K
- Pfizer$2K
- Lilly USA, LLC$772
- Amgen$671
- plus $6K from 42 others
Across 6 payments — averaging $5714.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$34K
What the payments were for
- Consulting fees$1,9501%
- Speaking & faculty fees$167,13887%
- Travel & lodging$5,4023%
- Food & beverage$16,9529%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$191,463 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 54 | $98,310 |
| QuliptaAtogepant | 39 | $59,970 |
| Aimovig AutoinjectorErenumab-Aooe | 66 | $56,511 |
| Nurtec OdtRimegepant Sulfate | 28 | $41,681 |
| Emgality PenGalcanezumab-Gnlm | 28 | $29,172 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 25 | $21,377 |
| Gabapentin | 235 | $5,838 |
| Pyridostigmine Bromide | 43 | $5,303 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 28 | $1,609 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 65 | $1,546 |
| Levetiracetam | 49 | $1,286 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $1,019 |
| Ropinirole Hcl | 11 | $932 |
| Memantine Hcl | 23 | $885 |
| Duloxetine Hcl | 55 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $145,124 | $158,27993 claims |
| PfizerNurtec Odt | $1,540 | $41,68128 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $36 | $5,30343 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $54248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Lake Barrington
- Andrew GordonLake Barrington$765K
- George KatsamakisLake Barrington$190K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.